Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
32.29
-0.20 (-0.62%)
At close: Apr 21, 2026, 4:00 PM EDT
31.10
-1.19 (-3.69%)
After-hours: Apr 21, 2026, 5:56 PM EDT

Rigel Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
596784298253260455
Market Cap Growth
89.12%163.27%17.51%-2.54%-42.80%-23.26%
Enterprise Value
494.85652.18272.97249.22242.31350.45
Last Close Price
32.2942.8316.8214.5015.0026.50
PE Ratio
1.662.2016.99-10.07-4.36-24.09
Forward PE
8.0310.4917.39---
PS Ratio
2.032.661.662.172.163.05
PB Ratio
1.512.0090.60-8.85-19.1014.97
P/TBV Ratio
1.552.0690.48-8.81-18.7814.88
P/FCF Ratio
7.8810.379.48-44.14-3.5086.60
P/OCF Ratio
7.8810.379.47-44.14-3.5377.36
EV/Sales Ratio
1.682.221.522.132.022.35
EV/EBITDA Ratio
3.875.1010.33-12.94-4.44-30.92
EV/EBIT Ratio
3.945.2011.28-12.16-4.36-28.05
EV/FCF Ratio
6.548.628.68-43.40-3.2766.74
Debt / Equity Ratio
0.060.0615.94-1.84-2.970.68
Debt / EBITDA Ratio
0.420.422.27-3.15-0.76-2.70
Debt / FCF Ratio
0.710.711.91-10.55-0.565.82
Net Debt / Equity Ratio
-0.26-0.26-5.28-0.131.22-3.11
Net Debt / EBITDA Ratio
-0.79-0.79-0.66-0.190.318.33
Net Debt / FCF Ratio
-1.34-1.34-0.55-0.630.22-17.98
Asset Turnover
0.870.871.280.930.801.07
Inventory Turnover
2.242.243.240.970.220.26
Quick Ratio
2.082.081.881.641.512.21
Current Ratio
2.422.422.131.861.782.43
Return on Equity (ROE)
185.94%185.94%-137.92%118.75%-699.04%-55.63%
Return on Assets (ROA)
111.57%111.57%16.38%-16.29%-36.84%-9.31%
Return on Invested Capital (ROIC)
199.00%199.00%49.54%-61.97%-257.05%-70.74%
Return on Capital Employed (ROCE)
48.72%48.72%29.39%-30.81%-64.28%-14.42%
Earnings Yield
61.53%45.48%5.89%-9.93%-22.93%-4.15%
FCF Yield
12.68%9.65%10.55%-2.27%-28.53%1.15%
Buyback Yield / Dilution
-6.52%-6.52%-1.64%-2.06%0.00%-1.03%
Total Shareholder Return
-6.52%-6.52%-1.64%-2.06%0.00%-1.03%
Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q